Imeglyn 1000 Tablet contains Imeglimin 1000 mg, an oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. Imeglimin acts by improving pancreatic beta-cell function and enhancing insulin sensitivity in peripheral tissues, thereby contributing to better glycemic control. It exerts a dual mechanism of action by modulating mitochondrial bioenergetics, which leads to reduced hepatic glucose production and increased glucose uptake in muscle cells. Imeglyn 1000 is typically prescribed as monotherapy or as an adjunct to other antidiabetic agents when diet and exercise alone do not provide adequate glycemic control. Clinical studies have demonstrated that Imeglyn effectively lowers fasting plasma glucose and HbA1c levels with a favorable safety profile. Common adverse effects may include mild gastrointestinal symptoms such as nausea or diarrhea, which are generally transient. It is contraindicated in patients with severe renal impairment or known hypersensitivity to Imeglimin. Dose adjustments may be necessary in patients with moderate renal dysfunction. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Imeglyn 1000 Tablet should be used under medical supervision as part of a comprehensive diabetes management plan including lifestyle modifications.